# Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

> **NCT02892123** · PHASE1 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 279 (actual)

## Conditions studied

- HER2-expressing Cancers

## Interventions

- **DRUG:** ZW25 (Zanidatamab)
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Vinorelbine
- **DRUG:** Tucatinib
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT02892123
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02892123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02892123, "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02892123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*